Carnegie Investment Bank congratulates EXACT Therapeutics on the NOK 25 million private placement.
EXACT-Tx is a Norwegian clinical-stage precision medicine company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases.
The net proceeds will be used to (i) advance and conclude on the dose expansion part of the ACTIVATE study in patients with liver metastases and announce the top line results, (ii) expand and conclude on the ACT® platform utility in selected additional high-value areas through preclinical studies, including glioblastoma, (iii) focused business development efforts, pursuing productive leads in selected use areas of ACT® (iv) conclude a pre-IND process with the FDA, for the ENACT study and development programme in pancreatic cancer, and (v) general corporate purposes and IP.
Carnegie is proud to have acted as sole bookrunner in the private placement, and wishes to thank CEO Per Walday, CFO John M. Edminson, Caspar Foghsgaard, chairman Anders Wold and the rest of the EXACT-Tx team for or the vote of confidence.